Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. APLS
APLS logo

APLS News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

APLS News

Biogen Acquires Apellis to Strengthen Immunology Position

3h agoNASDAQ.COM

US Stocks Surge as Market Sentiment Improves

1h agoNASDAQ.COM

Investor Rights Law Firm Investigates Multiple Companies for Potential Violations

2h agoPRnewswire

Apellis Pharmaceuticals Acquired by Biogen for $5.6 Billion

5h agoseekingalpha

Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion

5h agostocktwits

Biogen to Acquire Apellis for $5.6 Billion

5h agoNASDAQ.COM

RTW Investments Acquires Stake in Apellis Pharmaceuticals

Mar 22 2026Fool

RTW Investments Acquires Stake in Apellis Pharmaceuticals

Mar 22 2026NASDAQ.COM

APLS Events

03/31 12:10
Apellis Stock Rises 135.8% to $40.30
Apellis is up 135.8%, or $23.20 to $40.30.
03/31 12:00
Major Averages Surge, S&P 500 and Nasdaq Weakest Since 2022
The major averages were sharply higher near noon, signaling a positive end to an otherwise difficult month in which the S&P 500 and Nasdaq are on track for their weakest performance since 2022. Oil prices remain higher amid continued conflict in the Middle East, though The Wall Street Journal is reporting that President Trump has told aides he may be willing to end military activities even if the Strait of Hormuz stayed mostly closed. CBS News reported, however, that Trump said the U.S. is not pulling assets from the Strait just yet. Tensions remain amid Iran's reported strikes on a Kuwaiti oil tanker in Dubai waters.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Nvidiaisin Marvellas part of a strategic partnership over silicon photonics technologyBiogenApellisfor $41 per share in cash at closing, or $5.6BEli LillyCentessafor $38 per share in cash plus one contingent value rightMcCormickwith Unilever'sFoods businessKKRand Taiyo2. WALL STREET CALLS:BernsteinWestern Digitalon attractive entry post selloff10x Genomicsto Outperform at William BlairPhreesiato Neutral or equivalent ratings at Baird, Truist, Citi and JPMorganTDColgate-Palmoliveon higher oil-based input costsWall Streetof MiniMedwith mostly Buy or equivalent ratings3. AROUND THE WEB:Swiss senior parliamentarians have told UBSexecutives they would create a compromise related to the new rules as Bern finalizes a decision on how much capital the bank should hold, FT saysJehoshaphat Research issued a cautious report on Techtronic, claiming "corporate abuses" at the companyIrenic Capital Management has built a position in Snapand is pushing for changes at the social media company to improve financial and operating performance, Bloomberg saysNetflixis considering expanding its current two-game package to four games, WSJ reportsAppeals court denies reviving criminal case against Boeing, Bloomberg says4. MOVERS:Agios Pharmaceuticalsincreases after announcing it will pursue U.S.WeRidegains after launching afare-charging operations in Dubai with UberAehr Testhigher after receiving afor wafer-level test and burn-in of silicon photonics integrated circuitsT1 Energylower afterand maintaining its guidance for FY26Constellation Energyfalls afterEPS estimates5. EARNINGS/GUIDANCE:Purple Innovationand provided guidance for Q1 and FY26FactSetand raised its guidance for FY26J.Jill, with EPS and revenue beating consensusTD Synnexwith CEO Patrick Zammit commenting, "We're pleased with how we've started fiscal 2026"Interactive Strengthfor FY26INDEXES:Near midday, the Dow was up 1.01%, or 458.32, to 45,674.46, the Nasdaq was up 1.86%, or 382.78, to 21,177.42, and the S&P 500 was up 1.38%, or 87.79, to 6,431.51.
03/31 12:00
Needham Downgrades Apellis to Hold Without Price Target
Needham downgraded Apellis (APLS) to Hold from Buy without a price target after the company entered into an agreement to be acquired by Biogen (BIIB) for $41.00 per share in cash at closing, or $5.6B. Apellis stockholders will also receive a contingent value right for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for Syfovre.

APLS Monitor News

Apellis Pharmaceuticals reaches 52-week high amid market gains

Mar 31 2026

Apellis Pharmaceuticals Faces Increased Bearish Sentiment Amid Options Activity

Jan 12 2026

APLS Earnings Analysis

Apellis Pharma Earnings: Growth & Strategic Developments- Intellectia AI™
1 years ago

People Also Watch